Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated ...

African scientists have developed a nanoscale drug delivery system to treat pericarditis, a drug-resistant and lethal ...

HealthDay News — Children face higher risks for vascular and inflammatory diseases up to 12 months after COVID-19 diagnosis, according to a study published in the December issue of The Lancet Child & ...

Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple ...

Dr. Vinay Prasad, the director of the FDA's vaccine division, did not provide data to back the claim in a memo sent to staff.

Vinay Prasad, the head of the US FDA's Center for Biologics Evaluations and Research which oversees vaccines, said that future vaccine approvals will face stricter standards in light of the deaths of ...

AL AIN, 11th November, 2025 (WAM) -- Under the supervision of the Department of Health – Abu Dhabi, Tawam Hospital, one of SEHA’s facilities and a subsidiary of PureHealth, has successfully introduced ...

The largest study of its kind has revealed that the Pfizer-BioNTech Covid-19 vaccine presents considerably fewer problems for children and young people than the virus itself. It comes amid previous ...

Chicago Fire forward/midfielder Chris Mueller announced Thursday that he is battling pericarditis and will miss the rest of the season. The Schaumburg native has not played in 2025, being listed as ...

The Food and Drug Administration (FDA) has expanded its warnings on Pfizer and Moderna COVID-19 vaccines about the risks of two heart conditions. These manufacturers, the two main COVID-19 vaccine ...

Kiniksa Pharmaceuticals announces Phase 2/3 trial for KPL-387, targeting recurrent pericarditis, expected mid-2025. Data available in late 2026. Kiniksa Pharmaceuticals announced that it is set to ...

LONDON, June 05, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases ...